



DI-086. REVIEW OF OFF-LABEL USE AND ECONOMIC IMPACT OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN A TERTIARY HOSPITAL

M.A. Ruiz Gómez¹, A. Ibáñez Zurriaga¹, E. Ramírez Herráiz¹, A. Aranguren Oyarzábal¹, E. Debén Tíscar¹, A. Morell Baladrón¹

¹Hospital Universitario La Princesa, Hospital Pharmacy, Madrid, Spain

OBJECTIVES

- To describe the off-label use of intravitreal dexamethasone implants (DEXi) in our hospital and to evaluate the cost of DEXi compared to the standard treatment in diabetic macular oedema (DMO), ranibizumab.


METHODS

- A longitudinal, retrospective and descriptive study was carried out on patients treated with at least one DEXi from June 2011 to January 2013.
- The next set of data was collected from medical records: (1) sex, (2) age at first DEXi, (3) diagnosis, (4) number of injections, (5) re-injection interval period (months). (3), (4) and (5) were distinguished for each eye.
- Annual costs for each eye treated with DEXi and ranibizumab* were estimated by multiplying the drug manufacturers' price by the estimated annual number of implants or injections, respectively.
 - Drug manufacturers' price: DEXi (Ozurdex®) → 950 € for each implant. Ranibizumab (Lucentis®) → 857.21 € for each vial.
 - Estimated annual number of DEXi implants = $\frac{12 \text{ months}}{\text{the median re-injection interval period (months) in this study}}$
 - Estimated annual number of ranibizumab 0,5mg injections = minimum of 6 and maximum of 12.
 - *Annual costs for each eye treated with ranibizumab were estimated regarding 2 scenarios:
 - Scenario A: 1 vial → 1 injection of 0,5mg.
 - Scenario B: 33% dose optimization: 2 vials → 3 injections of 0,5 mg. (Aseptic and controlled conditions in the pharmacy department)


RESULTS

NUMBER OF PATIENTS AND EYES WITH AT LEAST ONE DEXi

- 39 patients: 16 women. Median of age=74 years (57.75-78.75)
- 43 eyes. 12 eyes (40% of all DEXi prescriptions) received more than one DEXi
- Median of re-injection interval: 5 months (4.5-6)
- Estimated annual number of implants: 2.4




NUMBER OF PATIENTS RELATED TO OFF-LABEL USES



- Diabetic Macular Oedema **4 patients with DMO received DEXi in both eyes
- Cystic Macular Oedema not following either Branch Or Central Retinal Vein Occlusion
- Postsurgical Cystic Macular Oedema
- Cystic Macular Oedema secondary to Age-Related Macular Degeneration
- Choroidopathy-associated Choroidal Neovascular Membrane

ANNUAL COSTS FOR EACH EYE TREATED WITH RANIBIZUMAB/DEXi IN DMO



CONCLUSIONS

- A high proportion of DEXi prescriptions consisted of off-label use.
- DMO was the most common off-label use. However, DEXi did not mean any incremental annual cost compared to ranibizumab (the standard drug treatment) in DMO, even considering dose optimization.
- Further studies that better determine efficacy and safety in these patients are needed.